AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

โ† Trials
๐Ÿงช

Lesion-tailored, Fundus-controlled Perimetry in Geographic Atrophy (GA).

Recruitingn/aAges 65 Years - 90 YearsAllUniversity of Utah
๐Ÿ’ฌ

In plain words

What the trial is, and whether it could suit you

The goal of this observational study is to evaluate changes in retinal sensitivity over time in patients with geographic atrophy due to age related macular degeneration who are receiving pegcetacoplan as part of routine clinical care. The study aims to determine whether lesion tailored fundus-controlled perimetry can reliably measure functional changes near areas of atrophy and whether this testing can be implemented in everyday clinic care over 24 months. Participants will undergo repeated vision testing, standard eye imaging, and visual function questionnaires while continuing their prescribed treatment.

Sign in to get the eligibility rules as simple questions to take to your doctor.

๐Ÿ“‹ Eligibility rules (as published)
Inclusion Criteria: * Age 65-90 years. * Geographic Atrophy (GA) secondary to dry Age-related Macular Degeneration (AMD) in at least one eye with the following criteria: * GA lesion size between 1 and 15 mmยฒ (โ‰ˆ 0.4 to 6 disc areas) * GA borders must be at least 500 ฮผm from the edge of the 30ยฐ ร— 25ยฐ optical coherence tomography (OCT) image frame * No confluent GA extending into peripapillary atrophy * Receiving intravitreal pegcetacoplan per label (at least one injection before screening). * Best-corrected visual acuity (BCVA) of 0.1 - 1.0 logMAR (โ‰ˆ 20/20 to 20/200 Snellen) * Able to undergo mesopic FCP and required imaging. * Informed consent provided. Exclusion Criteria: * Currently or previously active exudative macular neovascularization in the study eye. * High refractive errors (\> ยฑ5.00 Diopters \[D\] spherical equivalent) and significant astigmatism (\> 2.50 D). * Ocular comorbidities likely to confound sensitivity or imaging (e.g., diabetic retinopathy with macular edema, retinal vein occlusion (RVO), inherited retinal disease, uncontrolled glaucoma). * Media opacity precluding reliable fundus-controlled perimetry (FCP) or imaging (e.g., dense cataract, corneal opacity, vitreous hemorrhage). * Any systemic condition judged likely to compromise participation, follow-up, or data integrity.
๐Ÿ’Š

What it tests

  • Not listed
๐Ÿ“

Where

1 site
University of Utah, Department of Ophthalmology, John A. Moran Eye Center
Salt Lake City, United States
๐Ÿค Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible โ€” always decide together with your own doctor.
๐Ÿ›ก๏ธ

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it โ€” not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use ยท Privacy